Cerebrospinal Fluid (CSF) Cell Counter Market Report 2024

This Cerebrospinal Fluid (CSF) Cell Counter market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The cerebrospinal fluid (CSF) cell counter market size has grown strongly in recent years. It will grow from $1.32 billion in 2023 to $1.41 billion in 2024 at a compound annual growth rate (CAGR) of 6.9%. The historical growth can be attributed to several factors, including the rising demand for advanced diagnostic tools, the increasing prevalence of cerebrospinal fluid-related diseases, heightened research and development activities, increased healthcare spending, and a surge in the number of clinical trials.

The cerebrospinal fluid (CSF) cell counter market size is expected to see strong growth in the next few years. It will grow to $1.86 billion in 2028 at a compound annual growth rate (CAGR) of 7.2%. The anticipated growth during the forecast period can be linked to several factors, including greater awareness of early diagnosis, an increase in the number of diagnostic laboratories, a growing demand for precision medicine, a higher prevalence of brain tumors, a rise in autoimmune diseases, and an increase in neurological disorders. Key trends expected during this period include advancements in technology, improvements in imaging technology, the rise of personalized medicine, the integration of machine learning, and the development of wearable devices.

The growing prevalence of neurological disorders is anticipated to drive the expansion of the cerebrospinal fluid (CSF) cell counter market. Neurological disorders, which impact the brain, spinal cord, and nerves, include conditions such as Alzheimer's, Parkinson's, epilepsy, and multiple sclerosis. These disorders lead to a range of physical and cognitive challenges. Factors contributing to the rise in neurological disorders include infections, traumatic injuries, environmental toxins, aging, and underlying health conditions like diabetes and hypertension. CSF cell counters are essential for analyzing cell counts and characteristics in cerebrospinal fluid, aiding in the diagnosis, monitoring, and management of conditions like infections, tumors, and neurodegenerative diseases. For example, in April 2022, the European Brain Council, a Belgium-based non-profit, reported that over 600 neurological diseases and nearly 300 psychiatric conditions affect millions globally. This includes 65 million people with epilepsy and 10.5 million individuals in Europe with dementia, with projections suggesting a rise to 18.7 million by 2050. This increasing prevalence of neurological disorders is fueling the growth of the CSF cell counter market.

Key players in the CSF cell counter market are concentrating on developing innovative products to improve efficiency and accuracy in cell counting. For instance, hematology analyzers specialized for CSF cell counting are designed to provide detailed information on cell types and quantities in cerebrospinal fluid, which is crucial for diagnosing and monitoring neurological conditions. In June 2024, Horiba Ltd., a Japan-based scientific and analytical instrument provider, introduced the Yumizen H550E, a compact hematology analyzer. This device performs complete blood count (CBC), white blood cell differential (DIFF), and erythrocyte sedimentation rate (ESR) tests from whole blood in just 60 seconds. The analyzer is versatile, suitable for critical care, oncology, infectious disease care, blood banks, satellite laboratories, and health centers.

In July 2022, ArchiMed SAS, a France-based investment firm, acquired Natus Medical Incorporated for $1.2 billion. This acquisition aims to expand ArchiMed's portfolio in the neurodiagnostic sector, enhance its diagnostic capabilities, and leverage Natus Medical's expertise and technology to strengthen its position in the healthcare market. Natus Medical Incorporated, USA-based, specializes in diagnostic and therapeutic products for newborn care, neurology, and neurodiagnostics, including equipment for analyzing cerebrospinal fluid.

Major companies operating in the cerebrospinal fluid (CSF) cell counter market are Merck KGaA, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Corning Incorporated, Agilent Technologies Inc., Olympus Corporation, Eppendorf, Bio-Rad Laboratories Inc., Sysmex Corporation, Tecan Group, Natus Medical Incorporated, Advanced Instruments, ChemoMetec A/S, NanoEntek Inc., Logos Biosystems, Oxford Optronix Ltd., Nexcelom Bioscience, DeNovix Inc., Cypress Diagnostics.

North America was the largest region in the cerebrospinal fluid (CSF) cell counter market in 2023. The regions covered in the cerebrospinal fluid (CSF) cell counter market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the cerebrospinal fluid (CSF) cell counter market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cerebrospinal fluid (CSF) cell counter is a specialized tool used to measure and analyze the number of cells in cerebrospinal fluid samples. It aids in diagnosing and monitoring conditions that affect the central nervous system, such as infections, inflammation, and cancers.

There are several types of CSF cell counters, including fixed-type, portable-type, and other variations. Fixed-type CSF cell counters are stationary devices typically found in laboratories or healthcare settings. They are designed for high-volume testing and offer advanced features for precise analysis of CSF samples. These counters come with various products such as instruments, consumables and accessories, and software, and are used in different fields including hospitals, diagnostic laboratories, pharmaceutical and biotechnology sectors, and research institutes.

The cerebrospinal fluid (CSF) cell counters market research report is one of a series of new reports that provides cerebrospinal fluid (CSF) cell counters market statistics, including cerebrospinal fluid (CSF) cell counters industry global market size, regional shares, competitors with a cerebrospinal fluid (CSF) cell counters market share, detailed cerebrospinal fluid (CSF) cell counters market segments, market trends and opportunities, and any further data you may need to thrive in the cerebrospinal fluid (CSF) cell counters industry. This cerebrospinal fluid (CSF) cell counters market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cerebrospinal fluid (CSF) cell counter market consists of revenues earned by entities by providing services such as cell counting and analysis, clinical diagnostics, quality control, and data interpretation and reporting. The market value includes the value of related goods sold by the service provider or included within the service offering. The cerebrospinal fluid (CSF) cell counter market consists of sales of automated cell counters, flow cytometers, and CSF analysis software. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.